COMMUNIQUÉS West-GlobeNewswire

UK’s Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions’ Fingerprint Drug Test to Enhance Workplace Safety

25/09/2024 - 14:30

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

25/09/2024 - 14:30

PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, announced [...]

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

25/09/2024 - 14:30

Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath LOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc [...]

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

25/09/2024 - 14:30

DENVER, Sept. 25, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on [...]

Coloplast A/S - Financial Calendar 2024-25

25/09/2024 - 14:29

Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards, Investor Relations [...]

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

25/09/2024 - 14:15

Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments Study results to be presented at the [...]

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

25/09/2024 - 14:00

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findings Data from over subcohort of 3,350 [...]

3Daughters Announces NIH to Support Testing of Novel Frameless Magnetic Copper IUD (3D-001) for Contraception

25/09/2024 - 14:00

NICHD to Support Evaluation of Copper Release Characteristics of 3D-001in a Preclinical Model, as Company Prepares for Phase 1 Clinical Trial MANSFIELD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- 3Daughters , Inc., a [...]

Haywood Street Community Development’s Nourish & Nest Brings Million Dollar Fundraising Goal Within Reach

25/09/2024 - 14:00

North Carolina Executives, James Beard Award Winning Chefs, Restaurants & Retailers Vital to Effort to Complete Much Needed Housing ASHEVILLE, N.C., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Haywood Street Community [...]

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

25/09/2024 - 14:00

SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to [...]

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

25/09/2024 - 14:00

– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30 th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in [...]

Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

25/09/2024 - 14:00

ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion Corporation and Aitia, an AI-enabled biotechnology [...]

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

25/09/2024 - 14:00

– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose – Completion of pre- Clinical Trial Application (CTA) meeting with Health Canada [...]

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit

25/09/2024 - 14:00

SAN CLEMENTE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, [...]

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

25/09/2024 - 14:00

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor Erasca is also evaluating naporafenib plus trametinib in the ongoing SEACRAFT-2 pivotal Phase 3 trial in NRAS-mutant melanoma where favorable [...]

Sensus Healthcare Sells SRT System to Providence Swedish Hospital

25/09/2024 - 14:00

Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancers BOCA RATON, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS ), a [...]

Elixirgen Therapeutics Receives Rare Pediatric Disease Designation for EXG-34217 in Dyskeratosis Congenita and Related Telomere Biology Disorders

25/09/2024 - 14:00

Elixirgen Therapeutics is currently enrolling patients in its Phase 1/2 trial evaluating EXG-34217 in patients with telomere biology disorders at Cincinnati Children’s Hospital Medical Center BALTIMORE, Sept. 25, 2024 ( [...]

Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

25/09/2024 - 14:00

DOYLESTOWN, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic [...]

Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent

25/09/2024 - 14:00

– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data underscore that alerting [...]